PanGen, CCMD Move Kidney Drug To Final Trials In Three Countries
This article was originally published in PharmAsia News
Executive Summary
PanGen Biotech and CCM Duopharma Biotech of Malaysia said they plan to begin Phase III trials this month of a biosimilar kidney-failure drug, the South Korea drug maker's PDA10 (epoetin-alfa).